Details
Stereochemistry | ACHIRAL |
Molecular Formula | C7H7ClNO2S.Na.3H2O |
Molecular Weight | 281.69 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.[Na+].CC1=CC=C(C=C1)S(=O)(=O)[N-]Cl
InChI
InChIKey=NZYOAGBNMCVQIV-UHFFFAOYSA-N
InChI=1S/C7H7ClNO2S.Na.3H2O/c1-6-2-4-7(5-3-6)12(10,11)9-8;;;;/h2-5H,1H3;;3*1H2/q-1;+1;;;
Tosylchloramide or N-chloro tosylamide, sodium salt, sold as chloramine-T, is an investigational animal drug used in the aquaculture industry and also is a very effective odor control compound. It has other applications that include: algaecide, bactericide, germicide, parasite control, and for drinking water disinfection. It is also highly effective against bacteria, viruses, and spores.
In the aquaculture and aquafarming industries, Chloramine -T (Tosylchloramide Sodium Salt) is used to treat external bacterial infections in salmonid fish such as koi, salmon, trout, and whitefish. In the personal care industry, it is used in hydrotherapy treatments to revitalize, maintain, and restore health.
Hydrotherapeutic applications include whirlpools, saunas, steam baths, foot baths, and sitz baths. Chloramine-T is also used for disinfection in saunas, solariums, gyms, sport centres, kitchens, sanitary facilities, and air conditioning units. As an anti-microbial agent,Chloramine-T (Tosylchloramide Sodium Salt) it has had widespread use in a broad range of practices, including medical, dental, verterinary food processing and agricultural. It also has been used in direct contact with tissues because it has a low degree of cytotoxicity. Within the United States of America, the use of Chloramine-T is more restricted. Disifin (Tosylchloramide) destroys DNA and thereby prevents microbes from. DISIFIN® Tablets are effective against a whole series of microorganisms, including grampositive and gram-negative bacteria,
enveloped and non-en reproducing.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL5978 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28499825 |
|||
Target ID: CHEMBL2922 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28499825 |
|||
Target ID: CHEMBL3335 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28499825 |
|||
Target ID: CHEMBL2364041 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Tosylchloramide sodium Approved UseThe proposed indication for horses is skin desinfection, especially treatment of phlegmone (cellulitis). |
PubMed
Title | Date | PubMed |
---|---|---|
Disifin (sodium tosylchloramide) and Toll-like receptors (TLRs): evolving importance in health and diseases. | 2007 Dec |
|
Bactericidal and cytotoxic effects of chloramine-T on wound pathogens and human fibroblasts in vitro. | 2007 Jun |
|
Induction of cytochrome P450-dependent mixed function oxidase activities and peroxisome proliferation by chloramine-T in male rat liver. | 2017 Aug |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28499825
Rats were treated orally with chloramine-T at doses of 1.25, 2.50, 5
and 10 mg/kg body weight (bw)/day for 6 days. The activities of CYP2E1, CYP1A1/2
CYP2B1/2, CYP3A4 and CYP4A1/2 enzymes significantly increased after treatment with
2.50, 5 and 10 mg/kg bw/day, in a dose-dependent manner as compared to control. This
effect was not observed after chloramine-T treatment at dose of 1.25 mg/kg bw/day.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17538259
Curator's Comment: In vitro study of various concentrations and exposure times to preparations containing human fibroblasts or 1.5 x 10 colony forming units per milliliter (CFU/mL) of 3 gram-positive bacteria-Staphylococcus aureus, methicillin-resistant S aureus, and vancomycin-resistant Enterococcus faecalis-and 2 gram-negative bacteria-Escherichia coli and Pseudomonas aeruginosa-with and without fetal bovine serum present.
Gram-positive growth is reduced by 95% to 100% after tosylchloramide treatment, regardless of dose, with or without serum. E coli (gram-negative; with/without serum) is reduced 94% to 100% at antiseptic concentrations of 300 and 400 ppm. At 200 ppm, E coli growth is fully inhibited without serum present and by 50% with serum. At 100 and 200 ppm, cell viability remains greater than 90% under all experimental conditions. A 300-ppm, 3-minute exposure to tosylchloramide results in cell viability of up to 70%, with longer exposures producing lower viabilities. In vitro, chloramine-T at 200 ppm for 5 to 20 minutes was effective against 3 virulent gram-positive bacteria without fibroblast damage. At 300 ppm and 3 and 5 minutes, 30% of fibroblasts were damaged and 95% to 100 % of E coli were inhibited, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28394
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
||
|
CFR |
21 CFR 556.118
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1592902
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | |||
|
53767
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | |||
|
m3345
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID6040795
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | |||
|
517414
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | |||
|
DBSALT002810
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | |||
|
4IU6VSV0EI
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | |||
|
20762
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
ALTERNATIVE | |||
|
C016300
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | |||
|
7080-50-4
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | |||
|
C77036
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | |||
|
CHEMBL1625750
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | |||
|
4IU6VSV0EI
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY | |||
|
CHLORAMINE-T
Created by
admin on Fri Dec 15 15:07:54 GMT 2023 , Edited by admin on Fri Dec 15 15:07:54 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD